Scout | Targeting Inflammasomes in HIV and Substance Use (R01 Clinical Trial Not Allowed)

This opportunity is no longer accepting applications.

grant

Targeting Inflammasomes in HIV and Substance Use (R01 Clinical Trial Not Allowed)

This grant opportunity aims to support research focused on understanding how inflammasomes contribute to brain damage caused by drug use and HIV infection. The goal is to identify the molecular and cellular markers involved in immune responses triggered by these conditions in people with substance abuse issues. This research could lead to new therapies targeting inflammasomes to treat inflamma…

Source

Agency: National Institutes of Health

Sub-agency: National Institute on Drug Abuse

Award

Award Ceiling: $500,000

Funding Amount: $500,000

Dates

Opportunity Released: October 29, 2024

Open for Submission: October 29, 2024

Submission Deadline: March 13, 2025

Application Window Closes: March 13, 2025

Keywords

inflammasomes

neuropathology

drug exposure

HIV infection

immune activation

molecular markers

CNS immune cells

substance abuse

neuroinflammation

immune dysregulation

Supporting Links

Documents

Similar Opportunities

Unlock similar opportunities

Get the full picture on this opportunity

Create a free Scout account to unlock everything you need to decide fast and win the grant.

Instant Fit Analysis

Let our grant expert AI score how well this opportunity aligns with your organization, strengths, gaps, and how to improve your chances of winning funding.
Deep agency & funder detail

Program context, sub-agency structure, and a full eligibility breakdown.
Source links & full documents

Jump straight to the solicitation and download every attachment.
Similar opportunities

Discover related funding matched to your work.

Get a Demo Sign Up

Already have an account? Sign In

Trusted by 500+ Happy Customers